Xeophin

Xeophin

Created using Figma
Xeophin has devised a funding route for developing XeRA - 1 Therapeutic for Rheumatoid Arthritis, but this provision far surpasses the promising medicinal interest. Zeofilin 's unique approach to biotech' s financing can change the paradigm of medical financing. Xeophin tokenizes 50% of the future royalties generated by XeRA - 1, funds its token owner, and benefits from its success. Our mission is to adopt our core technology and promote them through the 6 step process. The result is a transaction-aware IP protection technology portfolio and is tokenized. Later, Xeophin will provide value to the XeRA - 1 token owner and conduct commercialization activities to achieve a significant royalty agreement. The XERA1 token supported by the physical asset, XeRA-1 arthritis remedy, may rise in value when a milestone is hit on a commercial road. If you are alive, the token holder will get cash loyalty payments that match the income of XeRA - 1.
Risk: High
Aug 20, 2018
Feb 22, 2019
100% completed
Raised funds - no Data
past
Token Details
Accepted Currencies
ETH, BTC, FIAT
Company Details
Registered Country
Australia
Additional Details
KYC
Yes
Categories
Platform

About Xeophin

Xeophin Pt y Ltd is a Melbourne, Australia based, Biotech Company with a focus on imunomodulating technologies, and is commit ted to the research, development and commercialisation of new and novel medical treatment s, in a number of high grow th therapeutic areas such as inflammation.

Our mission and vision are simple: “Take our core technologies and drive them through our six step process. The outcome being a transaction ready and IP protected technolog y por t folio. From this Xeophin will under take commercialisation activities to achieve a significant royalt y deal, delivering value to our XeR A-1 Token holders”.

In his position as Chief Executive Of ficer, Troy Neilson brings significant, relevant and recent Biotech experience along with extensive management skills. Travis Molloy as Executive Chairman brings 15 years experience in the development stage Biotech space and governance. Caroline Cook as Non-Executive Director brings to the organisation a wealth of project management, outsourcing and leadership experience.

Xeophin is currently a private and unlisted Australian company. Formal policies and best practice from Corporate Governance to Financial Management have been implemented from inception. Xeophin will reorganise and transition it self into the USA , this entit y is referred to NewCo at this stage. It is the NewCo entit y that will seek SEC compliance and undertake the formal ICO*.

Xeophin Team

Verified 0%

Attention. There is a risk that unverified members are not actually members of the team

Travis Molloy Bsc
EXECUTIVE CHAIRMAN
unverified
Troy Neilson
CHIEF EXECUTIVE OFFICER & MANAGING DIRECTOR
unverified
Jason Yeates
CHIEF FINANCIAL OFFICER, SENIOR VICE PRESIDENT OF...
unverified
Patrick Mcmanamny
HEAD OF INTELLECTUAL PROPERTY
unverified
Susan Dexter
HEAD OF CMC & GMP
unverified
Caroline Cook
NON-EXECUTIVE DIRECTOR
unverified

Advisors

Verified 0%

Attention. There is a risk that unverified members are not actually members of the team

Goran Ando
CHAIRMAN, CLINICAL ADVISORY COMMITTEE
unverified

Xeophin Last News

  • Due to potential time differences in information updates, please verify the accuracy of each ICO project through its official website or other official communication channels.
  • This information is not intended as a recommendation or suggestion for ICO investment. Please conduct thorough research on the relevant information and make your own informed decision regarding ICO participation.
  • If you identify any issues or errors in this content, or if you wish to submit your own ICO project for listing, please contact us via email at info@icoholder.com.
Please read the disclaimer and risk warning. Show disclaimer and risk warning.